IL137979A0 - Production, release preparation for aii antagonist-sustained and use thereof - Google Patents

Production, release preparation for aii antagonist-sustained and use thereof

Info

Publication number: IL137979A0
Authority: IL; Israel
Prior art keywords: sustained; release preparation; production; aii antagonist; angiotensin
Prior art date: 1998-03-04

Application number

IL13797999A

Other languages

English (en)

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-04

Filing date

1999-03-03

Publication date

2001-10-31

1999-03-03 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

2001-10-31 Publication of IL137979A0 publication Critical patent/IL137979A0/xx

Links

102000005862 Angiotensin II Human genes 0.000 abstract 2
101800000733 Angiotensin-2 Proteins 0.000 abstract 2
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 2
229950006323 angiotensin ii Drugs 0.000 abstract 2
230000003042 antagnostic effect Effects 0.000 abstract 2
229920002988 biodegradable polymer Polymers 0.000 abstract 1
239000004621 biodegradable polymer Substances 0.000 abstract 1
230000036772 blood pressure Effects 0.000 abstract 1
230000027288 circadian rhythm Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003405 delayed action preparation Substances 0.000 abstract 1
239000002184 metal Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL13797999A 1998-03-04 1999-03-03 Production, release preparation for aii antagonist-sustained and use thereof IL137979A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP5236698		1998-03-04
PCT/JP1999/001011 WO1999044590A1 (en)	1998-03-04	1999-03-03	Sustained-release preparation for aii antagonist, production and use thereof

Publications (1)

Publication Number	Publication Date
IL137979A0 true IL137979A0 (en)	2001-10-31

Family

ID=12912818

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13797999A IL137979A0 (en)	1998-03-04	1999-03-03	Production, release preparation for aii antagonist-sustained and use thereof

Country Status (21)

Country	Link
US (2)	US6589547B1 (id)
EP (1)	EP1058541B1 (id)
KR (1)	KR20010086245A (id)
CN (1)	CN1291888A (id)
AT (1)	ATE258430T1 (id)
AU (1)	AU2745199A (id)
BR (1)	BR9908474A (id)
CA (1)	CA2318446C (id)
DE (1)	DE69914460T2 (id)
EE (1)	EE200000499A (id)
ES (1)	ES2214013T3 (id)
HU (1)	HUP0101439A3 (id)
ID (1)	ID25640A (id)
IL (1)	IL137979A0 (id)
LT (1)	LT4800B (id)
LV (1)	LV12585B (id)
NO (1)	NO20004350L (id)
PL (1)	PL342684A1 (id)
SK (1)	SK11902000A3 (id)
WO (1)	WO1999044590A1 (id)
ZA (1)	ZA991706B (id)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20010086245A (ko) *	1998-03-04	2001-09-10	다케다 야쿠힌 고교 가부시키가이샤	Ａⅱ 길항제용 서방성 제제, 그것의 제조 및 용도
EP1197223B1 (en)	1999-04-28	2005-02-16	Takeda Pharmaceutical Company Limited	Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
SE9903028D0 (sv) *	1999-08-27	1999-08-27	Astra Ab	New use
PL353199A1 (en)	1999-08-30	2003-11-03	Aventis Pharma Deutschland Gmbh	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
CA2400124C (en) *	2000-02-18	2010-12-14	Kazuaki Ikeya	Tnf-.alpha. inhibitors
EP1258254A4 (en) *	2000-02-21	2004-02-04	Takeda Chemical Industries Ltd	COMPOSITIONS FOR DELAYED DELIVERY OF PHYSIOLOGICALLY ACTIVE COMPOUNDS THAT ARE LOW WATER-SOLUBLE, METHOD FOR THE PRODUCTION AND USE THEREOF
CA2420055C (en) *	2000-08-25	2010-06-01	Takeda Chemical Industries, Ltd.	Fibrinogen-lowering agent
EP1329218A4 (en) *	2000-10-25	2007-04-04	Takeda Pharmaceutical	PREVENTIVE / REMEDY AGENTS FOR PORTAL HYPERTENSION
WO2002074340A1 (fr) *	2001-03-16	2002-09-26	Takeda Chemical Industries, Ltd.	Procede de fabrication d'une preparation a liberation continue
US20040219208A1 (en) *	2001-08-03	2004-11-04	Ryu Kawamura	Sustained-release medicines
BRPI0105509B8 (pt) *	2001-11-05	2021-05-25	Univ Minas Gerais	formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
US7812044B2 (en)	2001-11-13	2010-10-12	Takeda Pharmaceutical Company Limited	Anticancer agents
WO2003047573A1 (en) *	2001-12-03	2003-06-12	Takeda Chemical Industries, Ltd.	Insulin resistance improving agents
US7700074B2 (en) *	2002-02-07	2010-04-20	Pettegrew Jay W	Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7407778B2 (en) *	2002-02-07	2008-08-05	Pettegrew Jay W	Compounds, compositions and methods for treating neuropsychiatric disorders
EP1579872B8 (en) *	2002-12-27	2012-11-07	Takeda Pharmaceutical Company Limited	Body weight gain inhibitor
US20050038093A1 (en) *	2003-05-02	2005-02-17	Boehringer Ingelheim International Gmbh	Treating diabetic retinopathy with angiotensin II receptor blockers
US20060257842A1 (en) *	2003-05-29	2006-11-16	Pettegrew Jay W	Cryopreservation media and molecules
US7815894B2 (en) *	2003-05-29	2010-10-19	Jay W. Pettegrew	Compounds, compositions and methods for medical imaging of neuropsychiatric disorders
WO2005097109A1 (en) *	2004-04-01	2005-10-20	Daniel Batlle	Methods for achieving a protective ace2 expression level
ES2282062T1 (es)	2004-06-04	2007-10-16	Teva Pharmaceutical Industries Ltd.	Composicion farmaceutica que contiene irbesartan.
KR20070073872A (ko) *	2004-10-07	2007-07-10	다케다 야쿠힌 고교 가부시키가이샤	대사 증후군의 예방 또는 치료용 제제
WO2006046528A1 (ja) *	2004-10-29	2006-05-04	Kowa Co., Ltd.	糸球体疾患治療剤
JP2008530185A (ja) *	2005-02-21	2008-08-07	フラメル・テクノロジー	ロサルタンの経口医薬剤形態
EP1863801B1 (en) *	2005-03-30	2010-09-29	Takeda Pharmaceutical Company Limited	Benzimidazole derivative and use thereof
EP1926705B3 (en) *	2005-08-22	2010-09-15	Alembic Limited	Process for preparing valsartan
US20100016382A1 (en) *	2006-08-10	2010-01-21	Takeda Pharmaceutical Company Limited	Pharmaceutical composition
EP1897537A1 (en) *	2006-09-04	2008-03-12	Novartis AG	Composition comprising an angiotensin II receptor antagonist
PE20081364A1 (es) *	2006-09-04	2008-12-04	Novartis Ag	Composicion farmaceutica que comprende valsartan
EP1908469A1 (en)	2006-10-06	2008-04-09	Boehringer Ingelheim Vetmedica Gmbh	Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
NO347209B1 (no)	2006-12-18	2023-07-03	Takeda Pharmaceutical	Sammensetning med forlenget frigjøring og fremgangsmåte for å produsere det samme
CN101011393B (zh) *	2007-02-16	2010-10-06	广州柏赛罗药业有限公司	厄贝沙坦胃内滞留型缓释药物组合物
US9066936B2 (en) *	2007-03-28	2015-06-30	Takeda Pharmaceutical Company Limited	Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
US20110117194A1 (en) *	2008-04-29	2011-05-19	Hanall Biopharma Co., Ltd.	Pharmaceutical formulation containing angiotensin-ii receptor blocker
BRPI1013037A2 (pt)	2009-05-20	2019-09-24	Boehringer Ingelheim Ipharmaceuticals Inc	"solução farmacêutica oral de telmisartan"
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
MX2022000426A (es)	2019-07-09	2022-04-25	Boehringer Ingelheim Vetmedica Gmbh	Telmisartan para el tratamiento de la hipertension en perros.

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2751907A (en) *	1953-09-18	1956-06-26	Bishop & Co Platinum Works J	Pellet injector
JPS5671074A (en)	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en)	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	Imidazole derivative
IE802177L (en)	1980-10-21	1981-05-12	Takeda Chemical Industries Ltd	Imidazol-5-ylacetic acid derivatives
JPS58157768A (ja)	1982-03-16	1983-09-19	Takeda Chem Ind Ltd	４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
CA1334092C (en)	1986-07-11	1995-01-24	David John Carini	Angiotensin ii receptor blocking imidazoles
US4820843A (en)	1987-05-22	1989-04-11	E. I. Du Pont De Nemours And Company	Tetrazole intermediates to antihypertensive compounds
US5015651A (en)	1988-01-07	1991-05-14	E. I. Du Pont De Nemours And Company	Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en)	1988-01-07	1989-11-14	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking benzimidazoles
CA1338238C (en)	1988-01-07	1996-04-09	David John Carini	Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4898732A (en) *	1988-05-04	1990-02-06	The Clinipad Corporation	Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
DE3928177A1 (de)	1989-04-08	1991-02-28	Thomae Gmbh Dr K	Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IE64514B1 (en)	1989-05-23	1995-08-09	Zeneca Ltd	Azaindenes
DE69010076T2 (de) *	1989-05-25	1994-12-08	Takeda Chemical Industries Ltd	Transdermales therapeutisches Mittel.
CA2018443A1 (en)	1989-06-14	1990-12-14	Joseph A. Finkelstein	Imidazolyl-alkenoic acids
EP0479903B1 (en)	1989-06-30	1996-02-21	E.I. Du Pont De Nemours And Company	Substituted imidazoles useful as angiotensin ii blockers
CA2020073A1 (en)	1989-07-03	1991-01-04	Eric E. Allen	Substituted quinazolinones as angiotensin ii antagonists
EP0407342A3 (en)	1989-07-06	1991-07-10	Ciba-Geigy Ag	Pyrimidine derivatives
EP0409332A3 (en)	1989-07-19	1991-08-07	Merck & Co. Inc.	Substituted triazoles as angiotensin ii antagonists
US5225205A (en) *	1989-07-28	1993-07-06	Debiopharm S.A.	Pharmaceutical composition in the form of microparticles
DE69013607T2 (de)	1989-08-02	1995-03-02	Takeda Chemical Industries Ltd	Pyrazol-Derivate, Verfahren zu deren Herstellung und Anwendung.
IL95975A (en)	1989-10-24	1997-06-10	Takeda Chemical Industries Ltd	N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
EP0434038A1 (en)	1989-12-22	1991-06-26	Takeda Chemical Industries, Ltd.	Fused imidazole derivatives, their production and use
US5162326A (en)	1990-02-15	1992-11-10	Takeda Chemical Industries, Ltd.	Pyrimidinedione derivatives, their production and use
CA2036618C (en) *	1990-02-22	2002-10-29	Akira Morimoto	Fused thiophene derivatives, their production and use
IE912956A1 (en) *	1990-09-10	1992-03-11	Abbott Lab	Angiotensin ii receptor antagonists
US5171217A (en) *	1991-02-28	1992-12-15	Indiana University Foundation	Method for delivery of smooth muscle cell inhibitors
TW274551B (id)	1991-04-16	1996-04-21	Takeda Pharm Industry Co Ltd
CA2115990A1 (en) *	1991-08-19	1993-03-04	George Albert Boswell	Angiotensin ii receptor blocking imidazolinone derivatives
TW284688B (id) *	1991-11-20	1996-09-01	Takeda Pharm Industry Co Ltd
US5656297A (en)	1992-03-12	1997-08-12	Alkermes Controlled Therapeutics, Incorporated	Modulated release from biocompatible polymers
GB2272899A (en) *	1992-11-30	1994-06-01	Du Pont Merck Pharma	Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles
EP0603712B1 (en)	1992-12-22	2001-08-16	Takeda Chemical Industries, Ltd.	Heterocyclic compounds having angiotensin II antagonistic activity and use thereof
US5288720A (en) *	1993-04-23	1994-02-22	American Cyanamid Company	Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5721263A (en) *	1993-06-07	1998-02-24	Takeda Chemical Industries, Ltd.	Pharmaceutical composition for angiotensin II-mediated diseases
EP1155689B1 (en) *	1993-07-19	2006-09-20	Angiotech Pharmaceuticals, Inc.	Anti-angiogenic stents and methods of their preparation
JPH0789849A (ja)	1993-09-20	1995-04-04	Fujisawa Pharmaceut Co Ltd	徐放性製剤
AU6242096A (en) *	1995-06-27	1997-01-30	Takeda Chemical Industries Ltd.	Method of producing sustained-release preparation
AU726694B2 (en)	1996-03-29	2000-11-16	Smithkline Beecham Corporation	Eprosartan dihydrate and a process for its production and formulation
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
US6201002B1 (en) *	1997-01-10	2001-03-13	Merck & Co., Inc.	Method for reducing mortality with an angiotensin II antagonist
US5958884A (en) *	1997-04-11	1999-09-28	The Brigham And Women's Hospital, Inc.	Compositions and methods for treating erectile dysfunction
US6306826B1 (en) *	1997-06-04	2001-10-23	The Regents Of The University Of California	Treatment of heart failure with growth hormone
DE19741635A1 (de) *	1997-09-22	1999-03-25	Hoechst Marion Roussel De Gmbh	Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
KR20010086245A (ko) *	1998-03-04	2001-09-10	다케다 야쿠힌 고교 가부시키가이샤	Ａⅱ 길항제용 서방성 제제, 그것의 제조 및 용도

1999
- 1999-03-03 KR KR1020007008919A patent/KR20010086245A/ko not_active Abandoned
- 1999-03-03 ID IDW20001680A patent/ID25640A/id unknown
- 1999-03-03 EP EP99907846A patent/EP1058541B1/en not_active Expired - Lifetime
- 1999-03-03 PL PL99342684A patent/PL342684A1/xx unknown
- 1999-03-03 AT AT99907846T patent/ATE258430T1/de not_active IP Right Cessation
- 1999-03-03 HU HU0101439A patent/HUP0101439A3/hu unknown
- 1999-03-03 SK SK1190-2000A patent/SK11902000A3/sk unknown
- 1999-03-03 CA CA002318446A patent/CA2318446C/en not_active Expired - Fee Related
- 1999-03-03 AU AU27451/99A patent/AU2745199A/en not_active Abandoned
- 1999-03-03 IL IL13797999A patent/IL137979A0/xx unknown
- 1999-03-03 ZA ZA9901706A patent/ZA991706B/xx unknown
- 1999-03-03 BR BR9908474-0A patent/BR9908474A/pt not_active IP Right Cessation
- 1999-03-03 WO PCT/JP1999/001011 patent/WO1999044590A1/en not_active Ceased
- 1999-03-03 DE DE69914460T patent/DE69914460T2/de not_active Expired - Lifetime
- 1999-03-03 ES ES99907846T patent/ES2214013T3/es not_active Expired - Lifetime
- 1999-03-03 CN CN99803444A patent/CN1291888A/zh active Pending
- 1999-03-03 EE EEP200000499A patent/EE200000499A/xx unknown
- 1999-03-09 US US09/601,986 patent/US6589547B1/en not_active Expired - Fee Related
2000
- 2000-08-16 LV LVP-00-110A patent/LV12585B/en unknown
- 2000-08-31 LT LT2000082A patent/LT4800B/lt not_active IP Right Cessation
- 2000-09-01 NO NO20004350A patent/NO20004350L/no unknown
2003
- 2003-05-22 US US10/443,308 patent/US7294344B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
LV12585B (en)	2001-03-20
CN1291888A (zh)	2001-04-18
ATE258430T1 (de)	2004-02-15
EE200000499A (et)	2002-02-15
EP1058541A1 (en)	2000-12-13
LT2000082A (en)	2001-03-26
ZA991706B (en)	2000-10-03
NO20004350D0 (no)	2000-09-01
LT4800B (lt)	2001-06-25
US20030198676A1 (en)	2003-10-23
LV12585A (en)	2000-12-20
CA2318446C (en)	2008-09-23
HUP0101439A3 (en)	2002-09-30
CA2318446A1 (en)	1999-09-10
HUP0101439A2 (hu)	2001-10-28
US6589547B1 (en)	2003-07-08
BR9908474A (pt)	2000-12-05
ES2214013T3 (es)	2004-09-01
ID25640A (id)	2000-10-19
AU2745199A (en)	1999-09-20
KR20010086245A (ko)	2001-09-10
US7294344B2 (en)	2007-11-13
DE69914460T2 (de)	2004-10-28
EP1058541B1 (en)	2004-01-28
WO1999044590A1 (en)	1999-09-10
DE69914460D1 (de)	2004-03-04
PL342684A1 (en)	2001-07-02
NO20004350L (no)	2000-10-03
SK11902000A3 (sk)	2001-02-12

Publication	Publication Date	Title
IL137979A0 (en)	2001-10-31	Production, release preparation for aii antagonist-sustained and use thereof
CA2356310A1 (en)	2000-07-06	External preparations containing a basic drug
IS5404A (is)	2000-03-14	Lyfjablanda sem inniheldur klódrónat sem virkt innihaldsefni og síliseraðan örkristallaðan sellulósa sem burðarefni
BR0014651A (pt)	2002-06-18	Inibidores de adesão de célula mediada por "alfa" l beta2
FI973452A7 (fi)	1997-08-22	Nauhoitettu annosmuoto aktiivisen aineen pidennettyyn jakamiseen
DK1117383T3 (da)	2006-04-03	Doseringsformer omfattende terapeutisk formulering
FR2790955B1 (fr)	2003-01-17	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
BG66115B1 (bg)	2011-05-31	Използване на рамиприл или негова фармацевтично приемлива сол за предотвратяване на конгестивна сърдечна недостатъчност
DE69840645D1 (en)	2009-04-23	Benzamidinderivate
BG101893A (en)	1999-01-29	Nodulosporic acid derivatives
BR9804027A (pt)	2001-04-24	Novos beta-ceto ésteres
MXPA04004805A (es)	2004-08-11	Peptido novedoso que tiene un efecto inhibidor de la enzima convertidora de angiotensina.
MXPA02002452A (es)	2004-09-10	Agentes preventivos y terapeuticos para enfermedades de oftalmicas.
DE69521122D1 (de)	2001-07-05	2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
EP1020447A4 (en)	2000-11-15	PYRAZOLE-BASED COMPOUNDS AND PLANT DISEASE CONTROL AGENT
CO4940452A1 (es)	2000-07-24	Modificacion a cristal de una sustancia activa de medicamen- to
ATE326451T1 (de)	2006-06-15	Chinazolin derivate und therapeutische verwendungen davon
BR9812982A (pt)	2000-08-08	Agente anti-reumático
SE9704770D0 (sv)	1997-12-19	New use
FR2740337B1 (fr)	1997-11-21	Compositions pharmaceutiques stabilisees contenant un derive ayant une activite adrenergique
WO2001039741A3 (de)	2001-12-13	Mitomycin c-lösung
WO2003015614A3 (en)	2003-12-24	Use of clc3 chloride channel blockers to modulate vascular tone
WO2001019358A3 (en)	2001-10-04	Use dexrazoxane for treating psoriasis
NO20014889L (no)	2001-10-08	Fremgangsmåte for fremstilling av medisinske midler
TH52872A3 (th)	2002-09-04	สารสำเร็จรูปชนิดที่รักษาการปลดปล่อยได้สำหรับตัวต้านฤทธิ์ aii